ImmunoGen, Inc. logo

ImmunoGen, Inc.

NASDAQ:IMGN

Overview | Financials
Company Name ImmunoGen, Inc.
Symbol IMGN
Currency USD
Price 31.235
Market Cap 8,725,621,690
Dividend Yield 0%
52-week-range 3.61 - 31.25
Industry Biotechnology
Sector Healthcare
CEO Mr. Mark Joseph Enyedy
Website https://www.immunogen.com

An error occurred while fetching data.

About ImmunoGen, Inc.

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in

Related Stocks

Cue Health Inc. logo

Cue Health Inc.

HLTH

0.043 USD

Phibro Animal Health Corporation logo

Phibro Animal Health Corporation

PAHC

21.68 USD

Alphatec Holdings, Inc. logo

Alphatec Holdings, Inc.

ATEC

9.33 USD

AngioDynamics, Inc. logo

AngioDynamics, Inc.

ANGO

9.01 USD

Avid Bioservices, Inc. logo

Avid Bioservices, Inc.

CDMO

12.28 USD

Health Catalyst, Inc. logo

Health Catalyst, Inc.

HCAT

7.09 USD

TransMedics Group, Inc. logo

TransMedics Group, Inc.

TMDX

62.6 USD

Cutera, Inc. logo

Cutera, Inc.

CUTR

0.319 USD

Kymera Therapeutics, Inc. logo

Kymera Therapeutics, Inc.

KYMR

42.02 USD

Financials

Numbers are in millions USD

Numbers are in millions USD